Meiko Nishimura

4PUBLICATIONS
13CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Models of care and place of birth
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Sep 02, 2026
Real-world outcomes of datopotamab deruxtecan after trastuzumab deruxtecan in hormone receptor-positive, HER2-negative metastatic breast cancer.

|Jul 20, 2026
Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B).

|Dec 05, 2025
Retrospective analysis of survival of patients with HER2-positive breast cancer with microscopic residual invasive disease after neoadjuvant chemotherapy.

Meiko Nishimura, Takayuki Kobayashi, Yosuke Aoyama

|Dec 07, 2024
Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study.

Yosuke Aoyama, Yukinori Ozaki, Rika Kizawa

Pageof 1

Frequent Collaborators

3 joint publications

Yosuke Aoyama

3 joint publications

Yukinori Ozaki

3 joint publications

Nami Yamashita

3 joint publications

Toshimi Takano